Home › Funds › DEERFIELD MANAGEMENT COMPANY, L.P. › BBOT
DEERFIELD MANAGEMENT COMPANY, L.P. position in BBOT
BridgeBio Oncology Therapeutic Inc · Health Care
DEERFIELD MANAGEMENT COMPANY, L.P. reported holding 4,885,446 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$37.2M, representing 0.47% of its reported portfolio and ranking #47 among its reported holdings. DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DEERFIELD MANAGEMENT COMPANY, L.P.'s BBOT position evolved
DEERFIELD MANAGEMENT COMPANY, L.P. first disclosed a stake in BBOT in Q3 2025 at 4,885,446 shares (US$56.6M). The position peaked in Q4 2025 at 4,885,446 shares, worth US$61.2M. Across 4 filings, DEERFIELD MANAGEMENT COMPANY, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 4,885,446 shares valued at US$37.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 4.89M | $56.57M | New |
| Q4 2025 | 4.89M | $61.17M | Hold |
| Q1 2026 | 4.89M | $43.72M | Hold |
| Q2 2026 | 4.89M | $37.23M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), Omega Fund Management, LLC (US$25.1M), Alphabet Inc. (US$21.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $25.07M · Q2 2026
- Alphabet Inc. 2.82M sh · $21.51M · Q2 2026
- EcoR1 Capital, LLC 2.82M sh · $21.51M · Q2 2026
- Enavate Sciences GP, LLC 2.63M sh · $20.02M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Laurion Capital Management LP 2.00M sh · $15.26M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $7.76M · Q2 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Catalio Capital Management, LP 318.41K sh · $2.43M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
- Avidity Partners Management LP 43.85K sh · $334.16K · Q2 2026
More on DEERFIELD MANAGEMENT COMPANY, L.P.
FAQ
How long has DEERFIELD MANAGEMENT COMPANY, L.P. held BBOT?
DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is DEERFIELD MANAGEMENT COMPANY, L.P.'s current position in BBOT?
As of Q2 2026, DEERFIELD MANAGEMENT COMPANY, L.P. holds 4.89M shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $37.23M, representing 0.47% of its reported portfolio and ranking #47.
Has DEERFIELD MANAGEMENT COMPANY, L.P. been buying or selling BBOT?
In the latest 13F filing (Q2 2026), DEERFIELD MANAGEMENT COMPANY, L.P. held unchanged its position in BBOT. The position peaked in Q4 2025 at 4.89M shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, Omega Fund Management, LLC, Alphabet Inc., among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.